Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

Oral Oncology

Volumn 51, Issue 3, 2015, Pages 221-228

  Ritprajak, Patcharee ^a   Azuma, Miyuki ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Carcinogenesis; Epithelial mesenchymal transition; Head and neck cancer; Immune regulation; Immunotherapy; Keratinocytes; PD L1 (B7 H1 CD274); Squamous cell carcinoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; MICRORNA 20B; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; STAT PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

BLADDER CANCER CELL LINE; BLAST CELL; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL CANCER CELL LINE; EPITHELIUM CELL; GLIOMA CELL LINE; HUMAN; IMMUNOREGULATION; KERATINOCYTE; LUNG CANCER CELL LINE; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SQUAMOUS CELL CARCINOMA; UPREGULATION; ANIMAL; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK TUMOR; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD274; CARCINOMA, SQUAMOUS CELL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-GAMMA; JANUS KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84923090821     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.11.014     Document Type: Review

References (77)

1. R.J. Greenwald, G.J. Freeman, and A.H. Sharpe The B7 family revisited Annu Rev Immunol 23 2005 515 548
2. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 8 2008 467 477
3. S. Yao, Y. Zhu, and L. Chen Advances in targeting cell surface signalling molecules for immune modulation Nat Rev Drug Discov 12 2013 130 146
4. J.M. Reichert Antibodies to watch in 2014: mid-year update MAbs 6 2014 799 802
5. C.B. Thompson, and J.P. Allison The emerging role of CTLA-4 as an immune attenuator Immunity 7 1997 445 450
6. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
7. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
8. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, and H. Nishimura Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
9. H. Nishimura, T. Honjo, and N. Minato Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice J Exp Med 191 2000 891 898
10. A.J. Korman, K.S. Peggs, and J.P. Allison Checkpoint blockade in cancer immunotherapy Adv Immunol 90 2006 297 339
11. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
12. T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 2013 1212 1218
13. J. Weber, J.A. Thompson, O. Hamid, D. Minor, A. Amin, and I. Ron A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 2009 5591 5598
14. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, and L. Thomas Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
15. G. Graziani, L. Tentori, and P. Navarra Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer Pharmacol Res 65 2012 9 22
16. J.R. Thumar, and H.M. Kluger Ipilimumab: a promising immunotherapy for melanoma Oncology 24 2010 1280 1288
17. A. Ribas Tumor immunotherapy directed at PD-1 New Engl J Med 366 2012 2517 2519
18. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott Safety, activity, and immune correlates of anti-PD-1 antibody in cancer New Engl J Med 366 2012 2443 2454
19. E.J. Lipson, W.H. Sharfman, C.G. Drake, I. Wollner, J.M. Taube, and R.A. Anders Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2013 462 468
20. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, and W.H. Sharfman Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
21. J.M. Taube, A.P. Klein, J.R. Brahmer, H. Xu, X. Pan, and J.H. Kim Asscoaition of PD-1, PD-L ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 2014
22. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin Nivolumab plus ipilimumab in advanced melanoma New Engl J Med 369 2013 122 133
23. T. Yamazaki, H. Akiba, H. Iwai, H. Matsuda, M. Aoki, and Y. Tanno Expression of programmed death 1 ligands by murine T cells and APC J Immunol 169 2002 5538 5545
24. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
25. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, and D.B. Flies Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
26. A.D. Salama, T. Chitnis, J. Imitola, M.J. Ansari, H. Akiba, and F. Tushima Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis J Exp Med 198 2003 71 78
27. H. Dong, G. Zhu, K. Tamada, D.B. Flies, J.M. van Deursen, and L. Chen B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes Immunity 20 2004 327 336
28. N. Rodig, T. Ryan, J.A. Allen, H. Pang, N. Grabie, and T. Chernova Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis Eur J Immunol 33 2003 3117 3126
29. P. Youngnak-Piboonratanakit, F. Tsushima, N. Otsuki, H. Igarashi, U. Machida, and H. Iwai The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role Immunol Lett 94 2004 215 222
30. P. Youngnak-Piboonratanakit, F. Tsushima, N. Otsuki, H. Igarashi, K. Omura, and M. Azuma Expression and regulation of human CD275 on endothelial cells in healthy and inflamed mucosal tissues Scand J Immunol 63 2006 191 198
31. S.C. Liang, Y.E. Latchman, J.E. Buhlmann, M.F. Tomczak, B.H. Horwitz, and G.J. Freeman Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses Eur J Immunol 33 2003 2706 2716
32. A. Nakazawa, I. Dotan, J. Brimnes, M. Allez, L. Shao, and F. Tsushima The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells Gastroenterology 126 2004 1347 1357
33. Y. Cao, L. Zhang, Y. Kamimura, P. Ritprajak, M. Hashiguchi, and S. Hirose B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin Cancer Res 71 2011 1235 1243
34. M.M. Mazanet, and C.C. Hughes B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis J Immunol 169 2002 3581 3588
35. S.J. Lee, B.C. Jang, S.W. Lee, Y.I. Yang, S.I. Suh, and Y.M. Park Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274) FEBS Lett 580 2006 755 762
36. Y. Chen, J. Zhang, J. Li, L. Zou, T. Zhao, and Y. Tang Expression of B7-H1 in inflammatory renal tubular epithelial cells Nephron Exp Nephrol 102 2006 e81 92
37. M.E. Keir, S.C. Liang, I. Guleria, Y.E. Latchman, A. Qipo, and L.A. Albacker Tissue expression of PD-L1 mediates peripheral T cell tolerance J Exp Med 203 2006 883 895
38. S. Ueki, A. Castellaneta, O. Yoshida, K. Ozaki, M. Zhang, and S. Kimura Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation Hepatology 54 2011 216 228
39. X. Li, R. Deng, W. He, C. Liu, M. Wang, and J. Young Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease J Immunol 188 2012 724 734
40. A. Saha, K. Aoyama, P.A. Taylor, B.H. Koehn, R.G. Veenstra, and A. Panoskaltsis-Mortari Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality Blood 122 2013 3062 3073
41. N. Okiyama, and I.K. Stephan Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratiocytes J Autoimmun 53 2014 1 9
42. S.E. Strome, H. Dong, H. Tamura, S.G. Voss, D.B. Flies, and K. Tamada B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res 63 2003 6501 6505
43. Y. Ohigashi, M. Sho, Y. Yamada, Y. Tsurui, K. Hamada, and N. Ikeda Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 2005 2947 2953
44. F. Tsushima, K. Tanaka, N. Otsuki, P. Youngnak, H. Iwai, and K. Omura Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma Oral Oncol 42 2006 268 274
45. A.T. Parsa, J.S. Waldron, A. Panner, C.A. Crane, I.F. Parney, and J.J. Barry Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 2007 84 88
46. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
47. Y.A. Cho, H.J. Yoon, J.I. Lee, S.P. Hong, and S.D. Hong Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma Oral Oncol 47 2011 1148 1153
48. S. Lyford-Pike, S. Peng, G.D. Young, J.M. Taube, W.H. Westra, and B. Akpeng Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma Cancer Res 73 2013 1733 1741
49. O.C. Ukpo, W.L. Thorstad, and J.S. Lewis Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma Head Neck Pathol 7 2013 113 121
50. V. Velcheti, K.A. Schalper, D.E. Carvajal, V.K. Anagnostou, K.N. Syrigos, and M. Sznol Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 2014 107 116
51. P. Loke, and J.P. Allison PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Proc Natl Acad Sci USA 100 2003 5336 5341
52. J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, and D. Hetuin Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood 110 2007 296 304
53. Y. Qian, J. Deng, L. Geng, H. Xie, G. Jiang, and L. Zhou TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells Cancer Invest 26 2008 816 821
54. A. Kondo, T. Yamashita, H. Tamura, W. Zhao, T. Tsuji, and M. Shimizu Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes Blood 116 2010 1124 1131
55. S.K. Lee, S.H. Seo, B.S. Kim, C.D. Kim, J.H. Lee, and J.S. Kang IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells J Dermatol Sci 40 2005 95 103
56. J. Chen, Y. Feng, L. Lu, H. Wang, L. Dai, and Y. Li Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway Immunobiology 217 2012 385 393
57. A.Y. Gong, R. Zhou, G. Hu, X. Li, P.L. Splinter, and S.P. O'Hara MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes J Immunol 182 2009 1325 1333
58. H. Ghebeh, A. Tulbah, S. Mohammed, N. Elkum, S.M. Bin Amer, and T. Al-Tweigeri Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells Int J Cancer 121 2007 751 758
59. M. Marzec, Q. Zhang, A. Goradia, P.N. Raghunath, X. Liu, and M. Paessler Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) Proc Natl Acad Sci USA 105 2008 20852 20857
60. R. Yamamoto, M. Nishikori, M. Tashima, T. Sakai, T. Ichinohe, and A. Takaori-Kondo B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma Cancer Sci 100 2009 2093 2100
61. C.H. Squarize, R.M. Castilho, A.C. Abrahao, A. Molinolo, M.W. Lingen, and J.S. Gutkind PTEN deficiency contributes to the development and progression of head and neck cancer Neoplasia 15 2013 461 471
62. M. Cumberbatch, X. Tang, G. Beran, S. Eckersley, X. Wang, and R.P. Ellston Identification of a subset of human non-small cell lung cancer patients with high PI3Kbeta and low PTEN expression, more prevalent in squamous cell carcinoma Clin Cancer Res 20 2014 595 603
63. J. Zhu, L. Chen, L. Zou, P. Yang, R. Wu, and Y. Mao MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer Hum Immunol. 75 2014 348 353
64. A. Suzuki, S. Itami, M. Ohishi, K. Hamada, T. Inoue, and N. Komazawa Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation Cancer Res 63 2003 674 681
65. C. Xu, C.M. Fillmore, S. Koyama, H. Wu, Y. Zhao, and Z. Chen Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression Cancer Cell 25 2014 590 604
66. E.A. Akbay, S. Koyama, J. Carretero, A. Altabef, J.H. Tchaicha, and C.L. Christensen Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov 3 2013 1355 1363
67. K. Azuma, K. Ota, A. Kawahara, S. Hattori, E. Iwama, and T. Harada Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer Ann Oncol 25 2014 1935 1940
68. Y. Cao, L. Zhang, P. Ritprajak, F. Tsushima, P. Youngnak-Piboonratanakit, and Y. Kamimura Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis Cancer Res 71 2011 4737 4741
69. V. Bolos, H. Peinado, M.A. Perez-Moreno, M.F. Fraga, M. Esteller, and A. Cano The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors J Cell Sci 116 2003 499 511
70. Y. Kang, and J. Massague Epithelial-mesenchymal transitions: twist in development and metastasis Cell 118 2004 277 279
71. L.G. Hudson, C. Choi, K.M. Newkirk, J. Parkhani, K.L. Cooper, and P. Lu Ultraviolet radiation stimulates expression of Snail family transcription factors in keratinocytes Mol Carcinogen 46 2007 257 268
72. M. Taki, N. Kamata, K. Yokoyama, R. Fujimoto, S. Tsutsumi, and M. Nagayama Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells Cancer Sci 94 2003 593 597
73. S.J. Grille, A. Bellacosa, J. Upson, A.J. Klein-Szanto, F. van Roy, and W. Lee-Kwon The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines Cancer Res 63 2003 2172 2178
74. K.A. Schalper PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer Oncoimmunology 3 2014 e29288
75. K.A. Schalper, V. Velcheti, D. Carvajal, H. Wimberly, J. Brown, and L. Pusztai In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas Clin Cancer Res 20 2014 2773 2782
76. A. Duray, S. Demoulin, P. Hubert, P. Delvenne, and S. Saussez Immune suppression in head and neck cancers: a review Clin Dev Immunol 2010 2010 701657
77. B.J. Park, S.I. Chiosea, and J.R. Grandis Molecular changes in the multistage pathogenesis of head and neck cancer Cancer Biomark 9 2010 325 339